ATE219580T1 - Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen - Google Patents

Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen

Info

Publication number
ATE219580T1
ATE219580T1 AT96903036T AT96903036T ATE219580T1 AT E219580 T1 ATE219580 T1 AT E219580T1 AT 96903036 T AT96903036 T AT 96903036T AT 96903036 T AT96903036 T AT 96903036T AT E219580 T1 ATE219580 T1 AT E219580T1
Authority
AT
Austria
Prior art keywords
dna
detection
telomeric
antibodies
binding
Prior art date
Application number
AT96903036T
Other languages
English (en)
Inventor
Eava-Marjatta Salonen
Original Assignee
Biohit Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oyj filed Critical Biohit Oyj
Application granted granted Critical
Publication of ATE219580T1 publication Critical patent/ATE219580T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT96903036T 1995-03-01 1996-02-29 Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen ATE219580T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI950962A FI100556B (fi) 1995-03-01 1995-03-01 Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä , reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten
PCT/FI1996/000117 WO1996027131A1 (en) 1995-03-01 1996-02-29 Anti dna antibody detection involving telomeric dna sequence recognition and binding

Publications (1)

Publication Number Publication Date
ATE219580T1 true ATE219580T1 (de) 2002-07-15

Family

ID=8542958

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903036T ATE219580T1 (de) 1995-03-01 1996-02-29 Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen

Country Status (9)

Country Link
EP (1) EP0812421B1 (de)
AT (1) ATE219580T1 (de)
AU (1) AU720912B2 (de)
DE (1) DE69621915T2 (de)
ES (1) ES2175069T3 (de)
FI (1) FI100556B (de)
NZ (1) NZ301725A (de)
WO (1) WO1996027131A1 (de)
ZA (1) ZA961628B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7018798B2 (en) * 1997-08-12 2006-03-28 Embedded Concepts, Llc Nucleic acid antigens embedded in thermoplastic
EP1274410A2 (de) * 2000-03-31 2003-01-15 Trustees Of Boston University Verwendung von lokal aplizierten dna-fragmenten
WO2005025650A1 (de) * 2003-09-12 2005-03-24 Frank Mattner Apherese-vorrichtung
SI24638A (sl) 2014-02-04 2015-08-31 Univerzitetni kliniÄŤni center Ljubljana Fluorometrična imunska metoda za določanje protiteles proti dvojnoverižni DNA
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE61670T1 (de) * 1985-06-25 1991-03-15 Progen Biotechnik Gmbh Immuntest zum nachweis von antikoerpern gegen dns.
AU1070588A (en) * 1987-01-30 1988-08-04 Diagnostic Products Corporation Measuring anti-dna antibodies
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity

Also Published As

Publication number Publication date
EP0812421A1 (de) 1997-12-17
FI100556B (fi) 1997-12-31
FI950962A0 (fi) 1995-03-01
AU720912B2 (en) 2000-06-15
DE69621915T2 (de) 2003-01-23
EP0812421B1 (de) 2002-06-19
DE69621915D1 (de) 2002-07-25
ES2175069T3 (es) 2002-11-16
AU4721596A (en) 1996-09-18
NZ301725A (en) 2001-02-23
FI950962A (fi) 1996-09-02
WO1996027131A1 (en) 1996-09-06
ZA961628B (en) 1996-08-08

Similar Documents

Publication Publication Date Title
HUP0102005A2 (hu) CD23 elleni antitestek, ezek származékai, és gyógyászati alkalmazásuk
DE69520149D1 (de) Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
ATE173544T1 (de) Parvovirusrezeptoren und verfahren zur ihrer verwendung
HUP9902327A2 (hu) Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
HK1048955A1 (zh) 朊病毒蛋白肽及其應用
HU9500673D0 (en) Novel rapamycin binding proteins and their diagnostic and therapeutic use
ATE219580T1 (de) Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
ATE335091T1 (de) Bc200 rna, daraus abgeleitete proben und entsprechende anwendungen
DK1128841T3 (da) Farmaceutisk præparat indeholdende en receptorantagonist til behandling af blodkoagulationsforstyrrelser
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DK0592600T3 (da) Protein S polypeptider og anvendelse deraf
WO2002070559A3 (en) Nuclear hormone receptor ligand binding domains
DE69529235D1 (de) Menschliche dnase i varianten
HUP0101689A2 (hu) Anti-gp39-ellenanyagok alkalmazása lupusz és ezzel asszociált vesebetegség kezelésére és/vagy visszafejlesztésére
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi
WO2002070561A3 (en) Nuclear hormone receptor ligand binding domain
WO2004005346A8 (en) Human nuclear hormone receptor
WO2004003010A3 (en) Nuclear hormone receptor ligano-binding domain containing protein
AU9134198A (en) T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions I
MX9709541A (es) Anticuerpos monoclonales de mono, especificos para las formas primatizadas de b7.1 y/o b7.2 humanos y composiciones farmaceuticas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties